Innovating Works

oncNGS

Financiado
NGS diagnostics in 21st century oncology the best for all at all times
oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecula... oncNGS consortium challenges the market to research and develop novel affordable solutions to provide the best NGS tests, for all solid tumours / lymphomas patients. The challenge will consist in providing: (1) efficient molecular DNA/RNA profiling of tumour-derived material in liquid biopsies by means of (2) pan-cancer tumour marker analysis kit including NGS analysis integrated with (3) an ICT decision support system including analytical test interpretation and reporting. Thanks to the provided solutions, oncNGS consortium will be able to address their common identified unmet medical needs: (1) Establishment of valuable common tumour profiling strategy allowing to provide equal access to innovative medicines to all; (2) Outcome research analysis after treatments with targeted therapies as diverse testing leads to lowering the pooling capacity of obtained results, needed to obtain large enough sample numbers to perform statistics analyses; (3) Application of such essential testing to all patients, breaking down current unacceptable inequities due to the high costs of current diagnostics tests. oncNGS is a strong consortium composed by eight buyers from five member states (SC and IJB from Belgium, IC and HCL from France, HC and LMU from Germany, ACC from Italy and ICO from Spain) supported by six entities with wide experience in their fields (AQuAS from Spain is expert in precommercial procurement, BCR from Belgium and INCa from France are experts in cancer control, IBSAL and VHIO are experienced in biomedical research in the field of haematologic malignancies and DCP is experts in intellectual property rights and freedom to operate analysis) oncNGS consortium will challenge the market launching a pre-commercial procurement procedure, a competitive process enabling the buyers to compare the developments carried out by the contracted suppliers through three phases: solution design, prototyping and clinical validation of a limited set of R&D supplies. ver más
30/04/2026
Sciensano
12M€
Duración del proyecto: 76 meses Fecha Inicio: 2019-12-13
Fecha Fin: 2026-04-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-12-13
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
SC1-BHC-10-2019: Innovation Procurement: Next generation sequencing (NGS) for routine diagnosis
Cerrada hace 5 años
Presupuesto El presupuesto total del proyecto asciende a 12M€
Líder del proyecto
SCIENSANO No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5